Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

@article{Gorlia2008NomogramsFP,
  title={Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.},
  author={Thierry Gorlia and Martin J. van den Bent and Monika E Hegi and Ren{\'e} Olivier Mirimanoff and Michael Weller and J. Gregory Cairncross and Elizabeth Eisenhauer and Karl B{\'e}langer and Alba A Brandes and Anouk Allgeier and Denis Lacombe and Roger Stupp},
  journal={The Lancet. Oncology},
  year={2008},
  volume={9 1},
  pages={29-38}
}
BACKGROUND A randomised trial published by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group (trial 26981-22981/CE.3) showed that addition of temozolomide to radiotherapy in the treatment of patients with newly diagnosed glioblastoma significantly improved survival. We aimed to undertake an exploratory subanalysis of the EORTC and NCIC data to confirm or identify new prognostic factors for survival in… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS